Image Credit: Boston Scientific
On Sept. 28, 2012 Boston Scientific announced that the FDA granted regulatory approval for its S-ICD® System, the world’s first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA). The S-ICD System sits entirely just below the skin without the need for leads to be placed into the heart.
Image Credit: Boston Scientific
Boston Scientific announced the exercise of its option to acquire Cameron Health. Cameron Health developed the world’s first and only commercially-available subcutaneous implantable cardioverter defibrillator – the S-ICD® System that I blogged about a few weeks ago.
The agreement calls for an upfront payment of $150 million, payable upon transaction closing, an additional potential $150 million payment upon FDA approval of the S-ICD System, plus up to an additional $1.050 billion of potential payments upon achievement of specified revenue-based milestones over a six-year period following FDA approval. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second or third quarter of 2012.
Cameron Health was founded in 2000 in San Clemente, CA to develop a leadless implantable defibrillator.
The device does not require a lead to be implanted into the heart. Instead, the device has a lead that is tunneled beneath the skin from the upper left chest below the level of the clavicle to the level of about the breast, then tunneled laterally to the side of the chest beneath the arm. The device uses the subcutaneous lead to sense the heart rhythm and can detect rapid arrhythmias from the surface ECG created between the lead electrode and the can of the device. Its maximum shocking output is 80 joules. Continue reading